THROUGH UNIVERSITY RESEARCH AND DEVELOPMENT
With teams at Western University, CanaQuest Medical Corp has created a number of patentable product formulations. Our research and product development focuses on health products and nutraceuticals utilizing cannabis and botanical oil extracts including algae oils.
To learn more about our value proposition and the benefits of our commercial-ready products, click the following link: CanaQuest Presentation.
Click picture above to see full-sized image.
PRODUCT FORMULATIONS
A critical mass of clinical evidence regarding the efficacy of medical cannabis is refuting political, scientific, and other skeptics, and opening minds hardened by decades of anti-cannabis propaganda. Our goal is to develop better alternative treatments to traditional pharmaceuticals for people struggling with a variety of health challenges.
CQ1 (Mentabinol®)
Commercial ready and effective for anxiety, depression, schizophrenia, and more.
CQ2 (Coming Soon)
Effective for anxiety, PTSD (chronic stress induced), pain and addiction.
CQ3
Effective for therapies for specific mental health symptom clusters.
CQ4
Effective for mitigation of the spread of cancerous tumors.
FOCUS AREAS
Anxiety
Addiction
Depression
Schizophrenia
PTSD
Pain
OUR VISION
Our vision is to be a global leader in the formulation and development of health products from cannabis derivatives.
IN THE NEWS
CanaQuest Medical Corp. Joins Stock Day Podcast to Discuss Global Expansion Plans
Phoenix, Arizona--(Newsfile Corp. - November 25, 2019) - The Stock Day Podcast welcomed CanaQuest Medical Corp. (OTC Pink: CANQF) ("the Company"), a company engaged in the development of unique health products and nutraceuticals that utilize hemp, cannabis and [...]
CanaQuest Medical Corp is the Winner of the Go Global Awards “Business of the Year – Category of Life Science” presented by the International Trade Council
Research & development is a primary focus for this medical cannabis company TORONTO − October 29, 2019 − CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”) announces that it has won the Go Global Awards [...]
CanaQuest Medical Corp announces Filing of International Cannabis Patent
A NOVEL BOTANICAL AND TETRAHYDROCANNABINOL (“THC”) FORMULATION FOR THE REDUCTION OF CANNABIS-INDUCED NEGATIVE NEUROPSYCHIATRIC SIDE-EFFECTS Research & development a primary focus for this medical cannabis company TORONTO – September 17, 2019 − CANAQUEST MEDICAL CORP (OTC Markets: [...]